trial

Ginkgo Biloba Extract in the Treatment of Schizophrenia

NCTId NCT05258123
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 100 (actual)
Sponsored by Beijing HuiLongGuan Hospital
Primary completion 2018-06-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2017-05-15
Primary completion
2018-06-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Ginkgo Biloba Extract

Sponsors

Beijing HuiLongGuan HospitalLead Sponsor

Investigators

1
Xiang Y Zhang, M.D, Ph.DPrincipal Investigator

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
100
Phase
NA
Primary Completion Date
2018-06-12
Status
COMPLETED
relationships
The graph out of here
drug
Ginkgo Biloba Extract
drug
lead_sponsor
Beijing HuiLongGuan Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Xiang Y Zhang, M.D, Ph.D
person